Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants.

International journal of pharmaceutical compounding - 1 Jan 2000

Riepl Mike

Abstract excerpt

COVID-19 (coronavirus disease 2019), which is caused by the positive-stranded ribonucleic acid virus SARS-CoV-2 (acute respiratory syndrome coronavirus 2), is an extremely contagious airborne illness of pandemic proportions. In the modern era, few diseases other than COVID-19 have produced such severe, prolific, and protean short-term adverse effects and long-term sequelae. In addition, few other pandemics have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19
Share to Mutation
Share to SARS-CoV-2

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36720058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants.PMID 36720058Read ↗

A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies.Semantic proximity Read ↗

COVID-19: comprehensive review on mutations and current vaccines.Semantic proximity Read ↗

Druggable targets and therapeutic development for COVID-19Semantic proximity Read ↗

COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte.Semantic proximity Read ↗

One year update on the COVID-19 pandemic: Where are we now?Semantic proximity Read ↗

COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic StrategiesSemantic proximity Read ↗

A comprehensive review on efficient approaches for combating coronaviruses.Semantic proximity Read ↗

A comprehensive review on the global efforts on vaccines and repurposed drugs for combating COVID-19Semantic proximity Read ↗

Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19Semantic proximity Read ↗

Comparative efficacy and safety of current drugs against COVID-19: A systematic review and network meta-analysisSemantic proximity Read ↗

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel StrategiesSemantic proximity Read ↗

Approaches to the Potential Therapy of COVID-19: A General Overview from the Medicinal Chemistry PerspectiveSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.